HEMATOLOGY
問題一覧
1
c. Constant systematic error
2
c. Control
3
b. Proficiency testing
4
a. Microtubules
5
d. Mitochondrion
6
d. Cyclin E/CDK2 complex
7
a. Stromal cells and growth factors
8
b. nuclear condensation
9
b. 5400 to 6600/µL
10
c. College of American Pathologists (CAP)
11
d. Lipid production and oxidation
12
d. The binding of soluble ligands to membrane receptors is not able to induce changes in gene expression.
13
a. Hematopoiesis
14
b. Apoptosis
15
c. Condensation of nuclear chromatin
16
a. Extramedullary hematopoiesis in the liver and spleen
17
b. Have the ability of self-renewal by asymmetric division
18
b. Stimulating EPO production by the kidney
19
d. Polychromatic normoblast
20
d. Promoting early release of reticulocytes from bone marrow
21
d. Maturing normoblasts slowly lose receptors for adhesive molecules that bind them to stromal cells.
22
c. Oxygen transport
23
a. Cytoskeletal proteins
24
a. Surrounding macrophages in erythroid islands
25
b. Embden-Meyerhof pathway
26
b. Methemoglobin reductase pathway
27
c. In two layers whose composition is asymmetric
28
a. Enhances O2 release from hemoglobin
29
d. Four heme molecules and four globin chains
30
d. F
31
b. Hemoglobin with iron in the ferric state (methemoglobin) and not able to carry oxygen
32
With a genes and ß genes on separate chromosomes, including two a genes on one chromosome and one ß gene on a different chromosome
33
a. α and β
34
d. iii, iv, i, v, ii
35
d. Rearrangement of antigen receptor genes
36
c. >95% Hb A, <3.5% Hb A2, 1% to 2% Hb F
37
c. Are largely composed of platelets and von Willebrand factor
38
d. Increasing the acute angle of the pusher slide
39
d. Two αβ dimers
40
b. It is recycled to the plasma membrane, where it can bind its ligand again.
41
d. comparison to a known physical constant
42
a. cephalic, basilic, and median cubital
43
d. both A and B
44
d. points of attachment of the spindle fibers
45
b. control of cellular function and transmission of genetic information
46
a. Use of the patient identifiers
47
b. active cell death
48
d. the plasma volume is decreased
49
a. expels 2,3-DPG
50
a. reduced amounts of glutathione
51
d. all of the above
52
c. enzyme activity, particularly glycolysis, decreases
53
c. two alpha and two beta chains
54
c. ingestion of lead
55
a. chromatin, nucleoli, and nucleoplasm
56
c. two alpha and two beta chains
57
d. two alpha and two gamma chains
58
c. sulfhemoglobin
59
a. substitution of a nonpolar amino acid residue for a polar residue near the surface of the chain
60
a. Source (anatomical site) of the blood or fluid
61
d. All of the above
62
a. two alpha and two delta chains
63
c. pernicious anemia
64
a. short, scalloped, or spike-like projections that are regularly distributed around the cell
65
c. the scooped-out part of an erythrocyte that remains after a blister cell ruptures
66
d. degree to which test data vary about the average
67
d. aggregates of iron, mitochondria, and ribosomes
68
a. incapable of combining with oxygen
69
b. the most predominant species worldwide; 12 to 24 merozoites; may contain Schüffner dots or granules
70
b. Nuclear maturation lags behind cytoplasmic maturation.
71
a. it drops in many patients because the circulating granulocytes are mobilized into the tissue site of infection
72
c. when bacteria enter the circulation
73
b. F
74
a. differentiate malignant disorders from leukemoid reactions
75
b. CLL
76
c. immediately precedes actual mitotic division
77
a. defend the body against disease
78
b. production of cytokines to shape type and strength of immune response
79
b. zeta chains and either epsilon or gamma chains
80
b. precipitated denatured hemoglobin
81
C. Nucleated RBCs are counted as leukocytes
82
A. Bizarre multinucleated erythroblasts
83
C. Decreased total iron-binding capacity (TIBC)
84
C. MCV 125 fL, MCH 36 pg, MCHC 34%
85
C. A shift-to-the-left increase in immature granulocytes
86
C. Normocytic, normochromic
87
C. Leukoerythroblastosis
88
C. Acute erythroid leukemia
89
B. Decreased plasma volume of circulating blood
90
C. MCV 80 μm3 MCH 36.5 pg MCHC 39.0%
91
C. G6PD deficiency
92
A. CML: low LAP; leukemoid: high LAP
93
C. Benign monoclonal gammopathy
94
C. 1:9
95
C. It is required for carboxylation of glutamate residues of some coagulation factors
96
D. Monoclonal against D-dimer
97
C. Escherichia coli 0157:H7
98
D. Immunologic fibrinogen level
99
D. Test has a negative predictive value
100
A. Decreased plasma iron, decreased % saturation, increased total iron-binding capacity (TIBC)
other names parasitology
other names parasitology
Yves Laure Pimentel · 70問 · 2年前other names parasitology
other names parasitology
70問 • 2年前PARASITOLOGY
PARASITOLOGY
Yves Laure Pimentel · 111問 · 2年前PARASITOLOGY
PARASITOLOGY
111問 • 2年前HTMLBE
HTMLBE
Yves Laure Pimentel · 64問 · 2年前HTMLBE
HTMLBE
64問 • 2年前CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
Yves Laure Pimentel · 61問 · 2年前CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
61問 • 2年前HISTOPATHOLOGY
HISTOPATHOLOGY
Yves Laure Pimentel · 69問 · 2年前HISTOPATHOLOGY
HISTOPATHOLOGY
69問 • 2年前CC-2 SPECTROPHOTOMETRY
CC-2 SPECTROPHOTOMETRY
Yves Laure Pimentel · 100問 · 2年前CC-2 SPECTROPHOTOMETRY
CC-2 SPECTROPHOTOMETRY
100問 • 2年前CC-3 ELECTROPHORESIS
CC-3 ELECTROPHORESIS
Yves Laure Pimentel · 41問 · 2年前CC-3 ELECTROPHORESIS
CC-3 ELECTROPHORESIS
41問 • 2年前AUBF LAB SAFETY
AUBF LAB SAFETY
Yves Laure Pimentel · 87問 · 2年前AUBF LAB SAFETY
AUBF LAB SAFETY
87問 • 2年前CSF 1
CSF 1
Yves Laure Pimentel · 100問 · 2年前CSF 1
CSF 1
100問 • 2年前CSF 2
CSF 2
Yves Laure Pimentel · 82問 · 2年前CSF 2
CSF 2
82問 • 2年前SEMEN 1
SEMEN 1
Yves Laure Pimentel · 100問 · 2年前SEMEN 1
SEMEN 1
100問 • 2年前SEMEN 2
SEMEN 2
Yves Laure Pimentel · 7問 · 2年前SEMEN 2
SEMEN 2
7問 • 2年前SYNOVIAL FLUID 1
SYNOVIAL FLUID 1
Yves Laure Pimentel · 100問 · 2年前SYNOVIAL FLUID 1
SYNOVIAL FLUID 1
100問 • 2年前SYNOVIAL FLUID 2
SYNOVIAL FLUID 2
Yves Laure Pimentel · 6問 · 2年前SYNOVIAL FLUID 2
SYNOVIAL FLUID 2
6問 • 2年前SEROUS FLUID
SEROUS FLUID
Yves Laure Pimentel · 25問 · 2年前SEROUS FLUID
SEROUS FLUID
25問 • 2年前PLEURAL FLUID
PLEURAL FLUID
Yves Laure Pimentel · 44問 · 2年前PLEURAL FLUID
PLEURAL FLUID
44問 • 2年前PERICARDIAL FLUID
PERICARDIAL FLUID
Yves Laure Pimentel · 18問 · 2年前PERICARDIAL FLUID
PERICARDIAL FLUID
18問 • 2年前PERITONEAL FLUID/ ASCITIC FLUID
PERITONEAL FLUID/ ASCITIC FLUID
Yves Laure Pimentel · 30問 · 2年前PERITONEAL FLUID/ ASCITIC FLUID
PERITONEAL FLUID/ ASCITIC FLUID
30問 • 2年前AMNIOTIC FLUID
AMNIOTIC FLUID
Yves Laure Pimentel · 92問 · 2年前AMNIOTIC FLUID
AMNIOTIC FLUID
92問 • 2年前FECALYSIS
FECALYSIS
Yves Laure Pimentel · 80問 · 2年前FECALYSIS
FECALYSIS
80問 • 2年前OTHER BODY FLUIDS
OTHER BODY FLUIDS
Yves Laure Pimentel · 89問 · 2年前OTHER BODY FLUIDS
OTHER BODY FLUIDS
89問 • 2年前MTLBE- SUHO NOTES
MTLBE- SUHO NOTES
Yves Laure Pimentel · 86問 · 2年前MTLBE- SUHO NOTES
MTLBE- SUHO NOTES
86問 • 2年前MTLBE..
MTLBE..
Yves Laure Pimentel · 35問 · 2年前MTLBE..
MTLBE..
35問 • 2年前CC- CHROMATOGRAPHY
CC- CHROMATOGRAPHY
Yves Laure Pimentel · 19問 · 1年前CC- CHROMATOGRAPHY
CC- CHROMATOGRAPHY
19問 • 1年前CC-OSMOMETRY
CC-OSMOMETRY
Yves Laure Pimentel · 14問 · 1年前CC-OSMOMETRY
CC-OSMOMETRY
14問 • 1年前CC-ELECTROCHEMISTRY TECHNIQUES
CC-ELECTROCHEMISTRY TECHNIQUES
Yves Laure Pimentel · 43問 · 1年前CC-ELECTROCHEMISTRY TECHNIQUES
CC-ELECTROCHEMISTRY TECHNIQUES
43問 • 1年前CC- CARBOHYDRATES
CC- CARBOHYDRATES
Yves Laure Pimentel · 49問 · 2年前CC- CARBOHYDRATES
CC- CARBOHYDRATES
49問 • 2年前CC- DIABETES MELLITUS
CC- DIABETES MELLITUS
Yves Laure Pimentel · 97問 · 2年前CC- DIABETES MELLITUS
CC- DIABETES MELLITUS
97問 • 2年前MAJOR LIPOPROTEINS
MAJOR LIPOPROTEINS
Yves Laure Pimentel · 57問 · 2年前MAJOR LIPOPROTEINS
MAJOR LIPOPROTEINS
57問 • 2年前MINOR LIPOPROTEINS
MINOR LIPOPROTEINS
Yves Laure Pimentel · 63問 · 2年前MINOR LIPOPROTEINS
MINOR LIPOPROTEINS
63問 • 2年前PROTEINS
PROTEINS
Yves Laure Pimentel · 37問 · 2年前PROTEINS
PROTEINS
37問 • 2年前PLASMA PROTEINS 1
PLASMA PROTEINS 1
Yves Laure Pimentel · 91問 · 2年前PLASMA PROTEINS 1
PLASMA PROTEINS 1
91問 • 2年前PLASMA PROTEINS 2 (ALPHA 2 REGION)
PLASMA PROTEINS 2 (ALPHA 2 REGION)
Yves Laure Pimentel · 98問 · 2年前PLASMA PROTEINS 2 (ALPHA 2 REGION)
PLASMA PROTEINS 2 (ALPHA 2 REGION)
98問 • 2年前MISCELLANEOUS PROTEINS
MISCELLANEOUS PROTEINS
Yves Laure Pimentel · 61問 · 2年前MISCELLANEOUS PROTEINS
MISCELLANEOUS PROTEINS
61問 • 2年前Liver Function Test 1
Liver Function Test 1
Yves Laure Pimentel · 100問 · 2年前Liver Function Test 1
Liver Function Test 1
100問 • 2年前Liver Function Test 2
Liver Function Test 2
Yves Laure Pimentel · 96問 · 2年前Liver Function Test 2
Liver Function Test 2
96問 • 2年前TUMOR MARKERS
TUMOR MARKERS
Yves Laure Pimentel · 33問 · 2年前TUMOR MARKERS
TUMOR MARKERS
33問 • 2年前KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
Yves Laure Pimentel · 41問 · 2年前KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
41問 • 2年前GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES
Yves Laure Pimentel · 17問 · 2年前GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES
17問 • 2年前LIPID STORAGE DISEASES
LIPID STORAGE DISEASES
Yves Laure Pimentel · 14問 · 2年前LIPID STORAGE DISEASES
LIPID STORAGE DISEASES
14問 • 2年前PROTEINS
PROTEINS
Yves Laure Pimentel · 71問 · 2年前PROTEINS
PROTEINS
71問 • 2年前QUICK FIRE- ELECTRODES
QUICK FIRE- ELECTRODES
Yves Laure Pimentel · 7問 · 2年前QUICK FIRE- ELECTRODES
QUICK FIRE- ELECTRODES
7問 • 2年前ELECTROLYTES
ELECTROLYTES
Yves Laure Pimentel · 10問 · 2年前ELECTROLYTES
ELECTROLYTES
10問 • 2年前DRUGS
DRUGS
Yves Laure Pimentel · 27問 · 2年前DRUGS
DRUGS
27問 • 2年前TOXIC AGENTS:
TOXIC AGENTS:
Yves Laure Pimentel · 12問 · 2年前TOXIC AGENTS:
TOXIC AGENTS:
12問 • 2年前HEMATOLOGY 1 (HEMATOPOIESIS 1)
HEMATOLOGY 1 (HEMATOPOIESIS 1)
Yves Laure Pimentel · 100問 · 2年前HEMATOLOGY 1 (HEMATOPOIESIS 1)
HEMATOLOGY 1 (HEMATOPOIESIS 1)
100問 • 2年前HEMATOLOGY (HEMATOPOIESIS 2)
HEMATOLOGY (HEMATOPOIESIS 2)
Yves Laure Pimentel · 29問 · 2年前HEMATOLOGY (HEMATOPOIESIS 2)
HEMATOLOGY (HEMATOPOIESIS 2)
29問 • 2年前hema diseases
hema diseases
Yves Laure Pimentel · 25問 · 2年前hema diseases
hema diseases
25問 • 2年前AML
AML
Yves Laure Pimentel · 43問 · 2年前AML
AML
43問 • 2年前GLOBIN SYNTHESIS
GLOBIN SYNTHESIS
Yves Laure Pimentel · 71問 · 2年前GLOBIN SYNTHESIS
GLOBIN SYNTHESIS
71問 • 2年前HEMATOLOGY REFERENCE RANGES
HEMATOLOGY REFERENCE RANGES
Yves Laure Pimentel · 31問 · 2年前HEMATOLOGY REFERENCE RANGES
HEMATOLOGY REFERENCE RANGES
31問 • 2年前DISORDERS OF PRIMARY HEMOSTASIS
DISORDERS OF PRIMARY HEMOSTASIS
Yves Laure Pimentel · 34問 · 2年前DISORDERS OF PRIMARY HEMOSTASIS
DISORDERS OF PRIMARY HEMOSTASIS
34問 • 2年前PLATELET DISORDERS
PLATELET DISORDERS
Yves Laure Pimentel · 37問 · 2年前PLATELET DISORDERS
PLATELET DISORDERS
37問 • 2年前CHARACTERISTICS OF CLOTTING FACTORS
CHARACTERISTICS OF CLOTTING FACTORS
Yves Laure Pimentel · 100問 · 2年前CHARACTERISTICS OF CLOTTING FACTORS
CHARACTERISTICS OF CLOTTING FACTORS
100問 • 2年前4. CLASSIFICATION OF MACROPHAGE
4. CLASSIFICATION OF MACROPHAGE
Yves Laure Pimentel · 12問 · 2年前4. CLASSIFICATION OF MACROPHAGE
4. CLASSIFICATION OF MACROPHAGE
12問 • 2年前3. NATURAL OR INNATE IMMUNITY
3. NATURAL OR INNATE IMMUNITY
Yves Laure Pimentel · 39問 · 2年前3. NATURAL OR INNATE IMMUNITY
3. NATURAL OR INNATE IMMUNITY
39問 • 2年前5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
Yves Laure Pimentel · 55問 · 2年前5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
55問 • 2年前6. PHAGOCYTOSIS Chemotaxis
6. PHAGOCYTOSIS Chemotaxis
Yves Laure Pimentel · 37問 · 2年前6. PHAGOCYTOSIS Chemotaxis
6. PHAGOCYTOSIS Chemotaxis
37問 • 2年前8. NATURE OF ANTIGEN
8. NATURE OF ANTIGEN
Yves Laure Pimentel · 44問 · 2年前8. NATURE OF ANTIGEN
8. NATURE OF ANTIGEN
44問 • 2年前9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
Yves Laure Pimentel · 50問 · 2年前9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
50問 • 2年前1. HISTORY
1. HISTORY
Yves Laure Pimentel · 69問 · 2年前1. HISTORY
1. HISTORY
69問 • 2年前2. TYPES OF IMMUNITY
2. TYPES OF IMMUNITY
Yves Laure Pimentel · 38問 · 2年前2. TYPES OF IMMUNITY
2. TYPES OF IMMUNITY
38問 • 2年前7. PHAGOCYTOSIS Engulfment and Digestion
7. PHAGOCYTOSIS Engulfment and Digestion
Yves Laure Pimentel · 21問 · 2年前7. PHAGOCYTOSIS Engulfment and Digestion
7. PHAGOCYTOSIS Engulfment and Digestion
21問 • 2年前8. PHAGOCYTOSIS EXOCYTOSIS
8. PHAGOCYTOSIS EXOCYTOSIS
Yves Laure Pimentel · 15問 · 2年前8. PHAGOCYTOSIS EXOCYTOSIS
8. PHAGOCYTOSIS EXOCYTOSIS
15問 • 2年前10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
Yves Laure Pimentel · 32問 · 2年前10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
32問 • 2年前11. TRANSPLANTATION IMMUNOLOGY
11. TRANSPLANTATION IMMUNOLOGY
Yves Laure Pimentel · 30問 · 2年前11. TRANSPLANTATION IMMUNOLOGY
11. TRANSPLANTATION IMMUNOLOGY
30問 • 2年前2. LYMPHOID ORGANS
2. LYMPHOID ORGANS
Yves Laure Pimentel · 38問 · 2年前2. LYMPHOID ORGANS
2. LYMPHOID ORGANS
38問 • 2年前3. CLUSTER OF DIFFERENTIATION
3. CLUSTER OF DIFFERENTIATION
Yves Laure Pimentel · 48問 · 2年前3. CLUSTER OF DIFFERENTIATION
3. CLUSTER OF DIFFERENTIATION
48問 • 2年前4. T-CELL DIFFERENTIATION
4. T-CELL DIFFERENTIATION
Yves Laure Pimentel · 35問 · 2年前4. T-CELL DIFFERENTIATION
4. T-CELL DIFFERENTIATION
35問 • 2年前5. T CELL IMMUNODEFICIENCIES
5. T CELL IMMUNODEFICIENCIES
Yves Laure Pimentel · 18問 · 2年前5. T CELL IMMUNODEFICIENCIES
5. T CELL IMMUNODEFICIENCIES
18問 • 2年前6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
Yves Laure Pimentel · 44問 · 2年前6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
44問 • 2年前7. B CELL IMMUNODEFICIENCIES
7. B CELL IMMUNODEFICIENCIES
Yves Laure Pimentel · 23問 · 2年前7. B CELL IMMUNODEFICIENCIES
7. B CELL IMMUNODEFICIENCIES
23問 • 2年前8. COMBINED T CELL AND B CELL DEFICIENCIES
8. COMBINED T CELL AND B CELL DEFICIENCIES
Yves Laure Pimentel · 34問 · 2年前8. COMBINED T CELL AND B CELL DEFICIENCIES
8. COMBINED T CELL AND B CELL DEFICIENCIES
34問 • 2年前9. COMPARISON OF T AND B CELLS
9. COMPARISON OF T AND B CELLS
Yves Laure Pimentel · 12問 · 2年前9. COMPARISON OF T AND B CELLS
9. COMPARISON OF T AND B CELLS
12問 • 2年前10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
Yves Laure Pimentel · 16問 · 2年前10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
16問 • 2年前11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
Yves Laure Pimentel · 15問 · 2年前11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
15問 • 2年前12. ANTIBODY
12. ANTIBODY
Yves Laure Pimentel · 79問 · 2年前12. ANTIBODY
12. ANTIBODY
79問 • 2年前13. TYPES OF ANTIBODIES
13. TYPES OF ANTIBODIES
Yves Laure Pimentel · 97問 · 2年前13. TYPES OF ANTIBODIES
13. TYPES OF ANTIBODIES
97問 • 2年前14. MONOCLONAL ANTIBODIES
14. MONOCLONAL ANTIBODIES
Yves Laure Pimentel · 11問 · 2年前14. MONOCLONAL ANTIBODIES
14. MONOCLONAL ANTIBODIES
11問 • 2年前1. INTERLEUKINS
1. INTERLEUKINS
Yves Laure Pimentel · 23問 · 2年前1. INTERLEUKINS
1. INTERLEUKINS
23問 • 2年前2. INTERFERONS
2. INTERFERONS
Yves Laure Pimentel · 28問 · 2年前2. INTERFERONS
2. INTERFERONS
28問 • 2年前3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
Yves Laure Pimentel · 8問 · 2年前3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
8問 • 2年前4. COMPLEMENT SYSTEM
4. COMPLEMENT SYSTEM
Yves Laure Pimentel · 19問 · 2年前4. COMPLEMENT SYSTEM
4. COMPLEMENT SYSTEM
19問 • 2年前15. COMPLEMENT SYSTEM
15. COMPLEMENT SYSTEM
Yves Laure Pimentel · 76問 · 2年前15. COMPLEMENT SYSTEM
15. COMPLEMENT SYSTEM
76問 • 2年前16. SYSTEM CONTROLS/COMPLEMENT REGULATION
16. SYSTEM CONTROLS/COMPLEMENT REGULATION
Yves Laure Pimentel · 21問 · 2年前16. SYSTEM CONTROLS/COMPLEMENT REGULATION
16. SYSTEM CONTROLS/COMPLEMENT REGULATION
21問 • 2年前17. COMPLEMENT AND DISEASE STATES
17. COMPLEMENT AND DISEASE STATES
Yves Laure Pimentel · 29問 · 2年前17. COMPLEMENT AND DISEASE STATES
17. COMPLEMENT AND DISEASE STATES
29問 • 2年前18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
Yves Laure Pimentel · 19問 · 2年前18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
19問 • 2年前19. CYTOKINES
19. CYTOKINES
Yves Laure Pimentel · 22問 · 2年前19. CYTOKINES
19. CYTOKINES
22問 • 2年前20. INTERLEUKINS
20. INTERLEUKINS
Yves Laure Pimentel · 24問 · 2年前20. INTERLEUKINS
20. INTERLEUKINS
24問 • 2年前21. INTERFERONS, TNF, TGF, CHEMOKINE
21. INTERFERONS, TNF, TGF, CHEMOKINE
Yves Laure Pimentel · 21問 · 2年前21. INTERFERONS, TNF, TGF, CHEMOKINE
21. INTERFERONS, TNF, TGF, CHEMOKINE
21問 • 2年前1. SERO
1. SERO
Yves Laure Pimentel · 54問 · 2年前1. SERO
1. SERO
54問 • 2年前2. PRECIPITATION
2. PRECIPITATION
Yves Laure Pimentel · 38問 · 2年前2. PRECIPITATION
2. PRECIPITATION
38問 • 2年前3. PASSIVE IMMUNODIFFUSION
3. PASSIVE IMMUNODIFFUSION
Yves Laure Pimentel · 17問 · 2年前3. PASSIVE IMMUNODIFFUSION
3. PASSIVE IMMUNODIFFUSION
17問 • 2年前4. OUCHTERLONY
4. OUCHTERLONY
Yves Laure Pimentel · 15問 · 2年前4. OUCHTERLONY
4. OUCHTERLONY
15問 • 2年前5. ELECTROPHORETIC TECHNIQUE
5. ELECTROPHORETIC TECHNIQUE
Yves Laure Pimentel · 9問 · 2年前5. ELECTROPHORETIC TECHNIQUE
5. ELECTROPHORETIC TECHNIQUE
9問 • 2年前6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
Yves Laure Pimentel · 11問 · 2年前6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
11問 • 2年前7. IMMUNOFIXATION ELECTROPHORESIS
7. IMMUNOFIXATION ELECTROPHORESIS
Yves Laure Pimentel · 29問 · 2年前7. IMMUNOFIXATION ELECTROPHORESIS
7. IMMUNOFIXATION ELECTROPHORESIS
29問 • 2年前問題一覧
1
c. Constant systematic error
2
c. Control
3
b. Proficiency testing
4
a. Microtubules
5
d. Mitochondrion
6
d. Cyclin E/CDK2 complex
7
a. Stromal cells and growth factors
8
b. nuclear condensation
9
b. 5400 to 6600/µL
10
c. College of American Pathologists (CAP)
11
d. Lipid production and oxidation
12
d. The binding of soluble ligands to membrane receptors is not able to induce changes in gene expression.
13
a. Hematopoiesis
14
b. Apoptosis
15
c. Condensation of nuclear chromatin
16
a. Extramedullary hematopoiesis in the liver and spleen
17
b. Have the ability of self-renewal by asymmetric division
18
b. Stimulating EPO production by the kidney
19
d. Polychromatic normoblast
20
d. Promoting early release of reticulocytes from bone marrow
21
d. Maturing normoblasts slowly lose receptors for adhesive molecules that bind them to stromal cells.
22
c. Oxygen transport
23
a. Cytoskeletal proteins
24
a. Surrounding macrophages in erythroid islands
25
b. Embden-Meyerhof pathway
26
b. Methemoglobin reductase pathway
27
c. In two layers whose composition is asymmetric
28
a. Enhances O2 release from hemoglobin
29
d. Four heme molecules and four globin chains
30
d. F
31
b. Hemoglobin with iron in the ferric state (methemoglobin) and not able to carry oxygen
32
With a genes and ß genes on separate chromosomes, including two a genes on one chromosome and one ß gene on a different chromosome
33
a. α and β
34
d. iii, iv, i, v, ii
35
d. Rearrangement of antigen receptor genes
36
c. >95% Hb A, <3.5% Hb A2, 1% to 2% Hb F
37
c. Are largely composed of platelets and von Willebrand factor
38
d. Increasing the acute angle of the pusher slide
39
d. Two αβ dimers
40
b. It is recycled to the plasma membrane, where it can bind its ligand again.
41
d. comparison to a known physical constant
42
a. cephalic, basilic, and median cubital
43
d. both A and B
44
d. points of attachment of the spindle fibers
45
b. control of cellular function and transmission of genetic information
46
a. Use of the patient identifiers
47
b. active cell death
48
d. the plasma volume is decreased
49
a. expels 2,3-DPG
50
a. reduced amounts of glutathione
51
d. all of the above
52
c. enzyme activity, particularly glycolysis, decreases
53
c. two alpha and two beta chains
54
c. ingestion of lead
55
a. chromatin, nucleoli, and nucleoplasm
56
c. two alpha and two beta chains
57
d. two alpha and two gamma chains
58
c. sulfhemoglobin
59
a. substitution of a nonpolar amino acid residue for a polar residue near the surface of the chain
60
a. Source (anatomical site) of the blood or fluid
61
d. All of the above
62
a. two alpha and two delta chains
63
c. pernicious anemia
64
a. short, scalloped, or spike-like projections that are regularly distributed around the cell
65
c. the scooped-out part of an erythrocyte that remains after a blister cell ruptures
66
d. degree to which test data vary about the average
67
d. aggregates of iron, mitochondria, and ribosomes
68
a. incapable of combining with oxygen
69
b. the most predominant species worldwide; 12 to 24 merozoites; may contain Schüffner dots or granules
70
b. Nuclear maturation lags behind cytoplasmic maturation.
71
a. it drops in many patients because the circulating granulocytes are mobilized into the tissue site of infection
72
c. when bacteria enter the circulation
73
b. F
74
a. differentiate malignant disorders from leukemoid reactions
75
b. CLL
76
c. immediately precedes actual mitotic division
77
a. defend the body against disease
78
b. production of cytokines to shape type and strength of immune response
79
b. zeta chains and either epsilon or gamma chains
80
b. precipitated denatured hemoglobin
81
C. Nucleated RBCs are counted as leukocytes
82
A. Bizarre multinucleated erythroblasts
83
C. Decreased total iron-binding capacity (TIBC)
84
C. MCV 125 fL, MCH 36 pg, MCHC 34%
85
C. A shift-to-the-left increase in immature granulocytes
86
C. Normocytic, normochromic
87
C. Leukoerythroblastosis
88
C. Acute erythroid leukemia
89
B. Decreased plasma volume of circulating blood
90
C. MCV 80 μm3 MCH 36.5 pg MCHC 39.0%
91
C. G6PD deficiency
92
A. CML: low LAP; leukemoid: high LAP
93
C. Benign monoclonal gammopathy
94
C. 1:9
95
C. It is required for carboxylation of glutamate residues of some coagulation factors
96
D. Monoclonal against D-dimer
97
C. Escherichia coli 0157:H7
98
D. Immunologic fibrinogen level
99
D. Test has a negative predictive value
100
A. Decreased plasma iron, decreased % saturation, increased total iron-binding capacity (TIBC)